SEC Form 4 · accession 0001179110-17-001952
ABIOMED INC · ABMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M Weber
Officer — Chief Operating Officer
Period of report
Feb 6, 2017
Accepted (ET)
Feb 8, 2017 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000815094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 par value | Feb 6, 2017 | M | 21,250 | $5.86 | A | 123,771 | D | |
| Common Stock, $.01 par valueF5 | Feb 6, 2017 | S | 500 | $105.368 | D | 123,271 | D | |
| Common Stock, $.01 par valueF6 | Feb 6, 2017 | S | 3,200 | $106.8891 | D | 120,071 | D | |
| Common Stock, $.01 par valueF7 | Feb 6, 2017 | S | 6,130 | $107.7193 | D | 113,941 | D | |
| Common Stock, $.01 par valueF8 | Feb 6, 2017 | S | 6,361 | $108.6569 | D | 107,580 | D | |
| Common Stock, $.01 par valueF9 | Feb 6, 2017 | S | 5,059 | $109.7788 | D | 102,521 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $5.86 | Feb 6, 2017 | M | 14,000 | D | May 28, 2010 | May 28, 2019 | Common Stock | 14,000 | 0 | D |
| Stock Options (right to buy)F2,F1 | $5.86 | Feb 6, 2017 | M | 7,250 | D | Mar 31, 2010 | May 28, 2019 | Common Stock | 7,250 | 21,250 | D |
| Stock Option (right to buy)F2,F1 | $10.03 | holding | — | — | — | Jun 3, 2011 | Jun 3, 2020 | Common Stock | 0 | 50,000 | D |
| Stock Option (right to buy)F2,F1 | $22.44 | holding | — | — | — | May 22, 2013 | May 22, 2022 | Common Stock | 0 | 25,000 | D |
| Stock Option (Right to Buy)F2,F1 | $23.15 | holding | — | — | — | May 14, 2014 | May 14, 2023 | Common Stock | 0 | 23,000 | D |
| Stock Option (Right to Buy)F2,F3 | $21.55 | holding | — | — | — | May 14, 2015 | May 14, 2024 | Common Stock | 0 | 15,000 | D |
| Stock Option (right to buy)F2,F3 | $66.25 | holding | — | — | — | May 13, 2016 | May 13, 2025 | Common Stock | 0 | 10,000 | D |
| Stock Option (right to buy)F4,F3 | $99.62 | holding | — | — | — | May 24, 2017 | May 24, 2026 | Common Stock | 0 | 7,000 | D |
Explanation of responses
- F1This option becomes exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- F2Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- F3These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- F4Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- F5This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $105.1100 and $105.7900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F6This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $106.2300 and $107.1700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F7This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $107.2500 and $108.2400. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F8This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $108.2600 and $109.2100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F9This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $109.3300 and $110.1600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.